TABLE 3

Patient Characterization and Image Scoring for Newly Detected Tumor Masses

Pathology	Patient no.	Serum folate (ng/mL)	Serum CA-125 (U/mL)	Age (y)	Folic acid dose (mg)	Image scoring*
											Masked		Unmasked
											A	B	A	B
Malignant	4	19.3	36	76	0	++	++	++	++	Mixed endometrioid and serous carcinoma
	7	10.0	1,221	49	5.0	++	++	++	++	Serous ovarian carcinoma
	8	9.6	69	61	5.0	++	++	++	++	Endometrioid adenocarcinoma
	11	16.4	1,632	76	0	++	++	++	++	Serous carcinoma
	13	12.2	410	52	0	++	++	++	++	Endometrial adenocarcinoma
	15	6.0		46	1.0	++	++	++	++	Ovarian adenocarcinoma
	37	5.2	2,123	55	2.0	++	++	++	++	Ovarian/mesodermal, carcinosarcoma
Borderline malignant	6		42	61	0	+	0	+	nr	Serous tumor (borderline malignancy)
Benign	5	6.4	67	54	0	0	0	0	0	Mature teratoma
	9	9.8		53	5.0	0	0	0	0	Simple serous cyst
	10	16.2	11	50	1.0	0	0	0	0	Serous cystadenofibroma
	14	>32.0		46	10.0	0	0	0	0	Ovarian endometrial cyst
	16	7.7	64	34	1.0	0	0	0	0	Endometriosis
	20	23.6	18	47	1.0	0	0	0	0	Myometrial leiomyomata
	21	8.2		38	1.0	0	0	0	0	Fibrovascular adhesions
	24	3.4	10	45	2.0	0	0	0	0	Brenner tumor
	25	12.4	229	47	1.0	0	0	0	0	Endometriosis
	35	15.4	<10	44	2.0	0	0	0	0	Serous cystadenoma
	36	16.1	<10	67	2.0	0	0	0	0	Hydrosalpinx
	27	36.0	30	39	1.0	0	nr	nr	nr	Mucinous cystadenoma
	29			82	0	0	nr	0	nr	Serous cystadenoma
	12	17.2		78	0	++	++	++	++	Adenomatoid hilar Leydig cell hyperplasia
	23	12.8	24	48	1.0	+	+	+	+	Endometriosis
	17	6.6	<10	52	0	++	++	0	0	Mature cystic teratoma
	22	52.9	141	37	2.0	++	+	++	0	Endometriosis
	34	11.1		68	2.0	0	0	0	+	Serous cystadenoma

↵* ++ = increased uptake of ¹¹¹In-DTPA-folate; + = faint uptake of ¹¹¹In-DTPA-folate; 0 = no uptake of ¹¹¹In-DTPA-folate; nr = images not read.